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Identiﬁcation of a Widespread Palmitoylethanolamide
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Roberto Angelini,1–3,{ Donovan A. Argueta,4,{ Daniele Piomelli,2,3 and Nicholas V. DiPatrizio4,*
Abstract
Introduction: Fatty acid ethanolamides (FAEs) are a family of lipid mediators that participate in a host of biolog-
ical functions. Procedures for the quantitative analysis of FAEs include organic solvent extraction from biological
matrices (e.g., blood), followed by puriﬁcation and subsequent quantitation by liquid chromatography–mass
spectrometry (LC/MS) or gas chromatography–mass spectrometry. During the validation process of a new
method for LC/MS analysis of FAEs in biological samples, we observed unusually high levels of the FAE, palmi-
toylethanolamide (PEA), in blank samples that did not contain any biological material.
Materials and Methods: We investigated a possible source of this PEA artifact via liquid chromatography
coupled to tandem mass spectrometry, as well as accurate mass analysis.
Results: We found that high levels of a contaminant indistinguishable from PEA is present in new 5.75'' glass
Pasteur pipettes, which are routinely used by laboratories to carry out lipid extractions. This artifact might ac-
count for discrepancies found in the literature regarding PEA levels in human blood serum and other tissues.
Conclusions: It is recommended to take into account this pitfall by analyzing potential contamination of the
disposable glassware during the validation process of any method used for analysis of FAEs.
Keywords: contamination; fatty acid ethanolamides; glass Pasteur pipettes; LC/MS; palmitoylethanolamide;
sample preparation
Introduction
Fatty acid ethanolamides (FAEs) are a family of endog-
enous lipid mediators, whose chemical structures con-
sist of a fatty acid moiety bound to ethanolamine by an
amide linkage. These compounds are synthesized by
cells throughout the body and control inﬂammation,
appetite and food intake, learning and memory, and
pain among other functions.1 Palmitoylethanolamide
(PEA) and oleoylethanolamide (OEA) suppress inﬂam-
mation by activating the ligand-operated transcription
factor, peroxisome proliferator-activated receptor-a
(PPAR-a).2 Anandamide (arachidonoylethanolamide
[AEA]) acts as a partial agonist at cannabinoid receptor
(CB) type 1 and 2 receptors and, therefore, belongs to
the diverse family of lipid signaling molecules called
endocannabinoids (ECBs).3,4
Due to their similar physicochemical properties,
FAEs and other ECBs, such as 2-arachidonoyl-sn-
glycerol (2AG), are usually coextracted from biological
samples.5 The procedure for their analysis includes ex-
traction with organic solvents (e.g., methanol and chlo-
roform) followed by puriﬁcation through solid-phase
extraction (e.g., open-bed silica gel) and subsequent
quantitation by liquid chromatography–mass spec-
trometry (LC/MS) or gas chromatography–mass spec-
trometry (GC/MS).
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FAEs are present in blood serum or plasma in the pmol
per mL scale and in biological tissues in concentration
ranging from the pmol to nmol per gram scale. A review
of the literature, however, reveals that data from different
laboratories, reporting concentration of FAEs in human
serum from healthy subjects, often do not corroborate
one another. In particular, reported levels of PEA and
OEA in serum or plasma of healthy human subjects differ
by up to two orders of magnitude, from 5 to 30pmol per
mL6–17 up to 200pmol per mL of serum or plasma.18,19
During the validation process of a new method for
LC/MS analysis of FAEs and ECBs in human serum ex-
tracts, we observed unexpectedly high levels of PEA, as
compared with data previously obtained in our labora-
tory.6 We suspected that these abnormal levels could be
due to a recurrent contamination. We found that 5''3 =4
Pasteur pipettes of most, if not all, commercial brands,
contain multiple contaminants detectable by LC/MS,
including readily detectable quantities of a compound
indistinguishable from PEA.
Materials and Methods
Materials
All solvents, including chloroform, methanol, and ace-
tone, were of the highest purity commercially available,
suggested for pesticide residue analysis, residue 1mg/L
max, from Burdick & Jackson (Honeywell International,
Inc., Morris Plains, NJ). Water was high-performance
liquid chromatography (HPLC) grade from Fisher
Scientiﬁc (Thermo Fisher Scientiﬁc, Inc., Waltham, MA).
Synthetic standards of FAEs, including deuterium-
containing internal standards (ISTDs) for isotope dilu-
tion ([2H4]PEA, [
2H4]OEA, [
2H4]AEA and [
2H5]2AG)
were purchased from Cayman Chemical (Ann Arbor,
MI). Ammonium acetate and acetic acid were Optima
grade from Fisher Chemical (Thermo Fisher Scientiﬁc,
Inc.). Disposable glass Pasteur pipettes (5''3 =4 and 9'' cor-
responding to 150 and 230mm, respectively) were from
the following vendors: Fisher Scientiﬁc (Thermo Fisher
Scientiﬁc, Inc.), VWR (VWR International LLC, Radnor,
PA), Corning (Corning, NY), and Wheaton (Wheaton
Industries, Inc., Millville, NJ). Eight milliliter vials were
from Thermo Scientiﬁc (Thermo Fisher Scientiﬁc,
Inc.). LC amber vials with inserts were from Agilent
Technologies (Santa Clara, CA). Beakers and cylinders
were from Fisher Scientiﬁc (Thermo Fisher Scientiﬁc,
Inc.). Glass syringes were from Hamilton (Reno, NV).
Silica Gel was 60Å 230–400 Mesh ASTM from What-
man, Inc. (Sigma-Aldrich Corp., St. Louis, MO).
Untreated glass wool was from Grace (Columbia, MD).
Extraction of FAEs from blood serum
Samples of human serum from healthy subjects were
kindly provided by Dr. Hamid Moradi. The study pro-
tocol was approved by the Institutional Review Board
of the University of California, Irvine and was com-
pleted with the assistance of the University of Cali-
fornia, Irvine, General Clinical Research Center.
Written informed consent was obtained from all sub-
jects. Blood samples were collected in red top blood
collection tubes (vacutainers, silicon-coated, and no
additives), which were left sitting upright at room tem-
perature for a minimum of 30min to a maximum of
60min to allow clotting. The blood sample was centri-
fuged immediately at the end of the clotting time in a
horizontal rotor (swing-out head) for 20min at 1100–
1300 g at room temperature. The serum was transferred
into labeled cryogenic vials, which were immediately
stored upright in a rack at 80C. Aliquot volume
was 1mL. This process was completed within 1 h of
centrifugation. Aliquots were transported in dry ice,
then slowly defrosted at 4C and stirred for 30 sec
prior use. A volume of serum of 0.6mL was trans-
ferred in an 8-mL glass vial. Protein precipitation
was performed by adding 1mL of cold acetone con-
taining deuterium-labeled ISTDs as follows: 1.2 pmol
of [2H4]PEA, 1.2 pmol of [
2H4]OEA, 0.6 pmol of
[2H4]AEA, and 30 pmol of [
2H5]2AG. Samples were
stirred for 60 sec then left in a cold room (4C) for
20min, then centrifuged at 2000 rpm at 4C for
20min. The supernatants were transferred with a Pas-
teur pipette in another 8-mL glass vial before undergo-
ing lipid extraction procedure. Lipid extraction was
performed using a modiﬁed Folch procedure,20 as fol-
lows. The excess of acetone was evaporated under N2.
Water was added up to 1mL of total volume and the
sample was vortexed for 60 sec. Then 1mL of methanol
was added and the sample vortexed for 60 sec. Finally,
2mL of chloroform was added and the sample vortexed
for 60 sec before centrifugation for 15min at 3500 rpm
at 4C. The lower chloroform phase was collected with
a Pasteur pipette and transferred in another glass vial,
evaporated under N2 stream, and reconstituted in
2mL of chloroform. Afterward, fractionation of the
lipid extract through open-bed chromatography was
performed as previously described.5 Brieﬂy, the stan-
dardized extraction procedure employed in our labora-
tory is an open-bed silica-gel column chromatography
(silica gel 60 230–400 mesh) that precedes LC/MS ana-
lyses (i.e., a custom-made solid-phase extraction proce-
dure). Silica gel columns were prepared as follows: a 5''3 =4
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glass Pasteur pipette was plugged with glass wool at the
beginning of the thin tip; 1mL of a slurry of silica gel
(60Å 230–400 Mesh ASTM) in chloroform (1:1, v/v)
was poured into the pipette held in a rack with a
metal tray underneath; the column was washed with
2mL of chloroform. The reconstituted 2mL of lipid ex-
tract was loaded onto the column. FAEs were eluted
with 2mL of chloroform/methanol (9:1, v/v). The elu-
ate was collected in another 8-mL glass vial, evapo-
rated under N2, reconstituted in 60lL of methanol,
and transferred in a 250-lL insert of a 2-mL LC vial be-
fore LC/MS analysis. The ﬁnal concentrations of ISTD
were, therefore, the following: 20 nM [2H4]PEA and
[2H4]OEA, 10 nM [
2H4]AEA and 500 nM [
2H5]2AG.
The same concentrations were used for the calibration
curves described in the LC/MS section below.
Pipette extraction
Disposable glass Pasteur pipettes were washed with 8mL
of chloroform. The chloroform was collected in an 8-mL
vial, spiked with 20 moles of ISTD [2H4]PEA, evaporated
under a stream of N2, reconstituted in 100lL of metha-
nol and transferred with a glass syringe in a 250-lL insert
of a 2-mL LC vial before LC/MS analysis. The ﬁnal con-
centration of [2H4]PEA ISTD was therefore 200nM.
Foam extraction
Polyurethane foam is used by vendors to wrap the glass
Pasteur pipettes to protect them from breakage. Small
pieces of this plastic material were cut and weighed.
Pieces of 1, 2.5, 5, and 10mg were deposited in 8-mL
glass vials that were previously washed with chloro-
form twice. Each vial was ﬁlled with 5mL of chloro-
form containing 20 pmol of ISTD [2H4]PEA. Vials
were stirred thoroughly. The chloroform was evapo-
rated under N2 and the extracts were suspended in
100 lL of methanol and transferred with a glass syringe
in a 250-lL insert of a 2-mL LC vial.
Transferring PEA from the foam to the glass
A PEA-free 9'' glass Pasteur pipette was further washed
with chloroform. The pipette was warmed up at 60C
and wrapped in polyurethane foam used by vendors
for packaging. Subsequently, a pipette extraction was
performed as described above to check whether PEA
could be transferred from the foam to the glass.
Liquid chromatography–mass spectrometry
LC/MS analyses of samples were performed using
an Agilent 1200 LC system coupled to an Agilent
G6410A triple quadrupole (QQQ) MS detector (Agi-
lent Technologies) equipped with an electrospray ion-
ization (ESI) interface. FAEs were separated using a
XDB Eclipse C18 column (2.1 · 50mm i.d., 1.8lm),
eluted with an isocratic method of methanol in water
(A: 20% water + 0.25% acetic acid + 5mM ammonium
acetate and B: 80% methanol + 0.25% acetic acid
+ 5mM ammonium acetate in 8min) at a ﬂow rate
of 0.4mL/min. Column temperature was kept at
40C. MS detection was in the positive mode, capillary
voltage was set at 4 kV, fragmentor voltage varied from
120 to 140V, and collision energy was 20 eV. Helium
was used as collision gas, whereas nitrogen was used
as a drying gas at a ﬂow rate of 12 liters/min at
350C. Nebulizer pressure was set at 50 PSI. In parallel,
LC/MS and tandem mass spectrometry (MS/MS) data
were also acquired on an ACQUITY UPLC I-Class sys-
tem coupled to a Xevo TQ-S Micro Mass Spectrometer
(Waters, Milford, MA) with accompanying ESI in-
terface (data presented in Fig. 3B, Supplementary
Figs. S5 and S7). On both set-ups we quantiﬁed FAEs
with an isotope dilution method, monitoring proton-
ated adducts of the molecular ions [M+H]+ in multiple
reaction-monitoring (MRM) mode. The MRM transi-
tions monitored for FAEs detection and quantitation
were the following: PEA (m/z=300.3> 62.1); OEA (m/z=
326.3>62.1); AEA (m/z= 348.3> 62.1); 2AG (m/z=
379.3>287.2); [2H4]PEA (m/z=304.3>66.1); [2H4]OEA
(m/z=330.3>66.1); [2H4]AEA (m/z=352.3> 66.1); and
[2H5]2AG (m/z = 384.3> 287.2). Additional analytes
were investigated on the Waters UPLC/MS/MS as possi-
ble contaminants in foam: docosahexaenoyl ethanolamide
(DHEA, Supplementary Fig. S5G, H) (m/z= 372.3>62.1),
and docosahexaenoyl glycerol (DHG, Supplementary
Fig. S5K, L) (m/z = 403.4 > 311.2). We used two differ-
ent sets of calibration curves, one for the serum analysis
with low ISTD and one for pipettes and foam extracts
with higher ISTD. In particular, we prepared standard
calibration curves by adding a constant amount of
deuterium-labeled standards to increasing amount of
the corresponding unlabeled FAEs, followed by MS
analysis as described above. The relative concentrations
of unlabeled versus labeled ions were plotted against
their relative response (i.e., peak area) and the calibra-
tion curves were constructed using linear regression. R2
was 0.998 for all analytes, indicating linear response. In
the calibration curve for serum extracts analysis, the
ISTDs were kept as follows: [2H4]PEA and [
2H4]OEA
at 20 nM, [2H4]AEA at 10 nM, and [
2H5]2AG at
500 nM. In the calibration curve for foam and pipette
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extracts analysis, the ISTD [2H4]PEA was kept at
200 nM. In both cases the nondeuterated reference
standard of PEA, OEA, AEA, and 2AG were at concen-
trations ranging from 1 nM to 2lM, for a total of 11
points of calibration.
Highly accurate mass data were obtained on a Shi-
madzu IT-TOF (ion trap–time-of-ﬂight) coupled to
Shimadzu Nexera HPLC system following a similar
LC/MS method. A reverse-phased endcapped C18 col-
umn from Knauer was employed (Eurospher II 100
C18: 2 · 100mm i.d., 3 lm, 100A). The solvent system
and oven temperature were the same as described
above for the Agilent instrument. The LC method
was 13min long and proceeded as follows: from 85
to 98%B in 5min, then kept at 98%B for 5min, fol-
lowed by a re-equilibration step at 85%B for 3min.
Source temperature was kept at 250C, drying gas pres-
sure was 103 kPa (10 L/min), detector voltage was
1.55 kV, and probe voltages were 4.5 and 3.5 kV.
Data were acquired and analyzed with the Shimadzu
software LCMS Solution (Acquisition and Analysis)
and Formula Predictor. All LC/MS data showed in
this article were obtained in the positive ion mode.
Results
Quantitation of FAEs and 2AG
in human serum samples
We quantiﬁed PEA, OEA, AEA, and 2AG levels in serum
samples from three healthy subjects. Table 1 contains a
comparison of average FAEs and 2AG levels, measured
in this work and by independent laboratories, in
human serum/plasma from healthy subjects, by LC/MS
analysis. For most compounds, concentrations measured
in the present study were in close agreement with those
previously reported by our group6 and others.7 PEA lev-
els were similar to those reported by Bilgin et al.18 and by
Sipe et al.,19 but 10 to 20 times higher than those reported
by other groups7–17 and previously by us.6 This suggested
that a contamination might be present.
Identiﬁcation of PEA in glass Pasteur
pipettes and plastic foam
First, all solvents were carefully checked as a possible
source of contamination. Skonberg et al.21 have
found that chloroform from certain vendors contained
small amounts of PEA. We could not conﬁrm those
ﬁndings: all solvents used during our procedure for ex-
traction of FAEs and ECBs from serum were found to
be FAEs free. This prompted us to carefully check all Ta
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the glassware, disposable and not, used to carry out the
extraction procedure. This included 2-mL LC vials, vial
inserts, 8-mL disposable glass vials, glass beakers, glass
solvents bottles, disposable glass Pasteur pipettes, and
the polyurethane foam used to wrap them. LC-MS
andMS/MS traces of authentic PEA standard and chlo-
roform–methanol washout of glass pipettes and ex-
tracts of polyurethane foam were recorded in the
positive ion mode. LC-MS data were acquired on two
separate QQQ instruments (Agilent G6410A and
Waters Xevo TQ-S Mass Spectrometer) and on a
high accuracy IT-TOF mass spectrometer (Shimadzu
IT-TOF) to conﬁrm identiﬁcation by accurate mass
measurement. Figure 1 shows the comparative LC-
MS (panel A) and LC-MS/MS (panel B) analysis of
PEA standard (traces a), pipette washout (traces b),
and foam extract (traces c) carried out on the Agilent
QQQ. The MS1 analysis in panel A shows the extracted
ion chromatograms (EIC) for the m/z 300.3 belonging
to the PEA-positive pseudomolecular ion [M+H]+.
These three chromatograms show coeluting peaks
at retention time (RT) 5.7min for the m/z 300.3. The
MS2 analysis in Figure 1B shows the fragmentation
pattern obtained by Collision-Induced Dissociation
(Fragmentor 135V, CID 20 eV) of the peaks at 300.3
in each chromatogram. The obtained MS/MS spectra
are superimposable and show peaks of the positive
pseudomolecular ion of PEA [M+H]+ at 300.3 Th,
the fragment deriving from the water loss [M+H-
H2O]
+ at 282.3 Th, and the diagnostic fragment of eth-
anolamine [Ethanolamine+H]+ at 62.1 Th. The signal
belonging to the ammonia loss (17) at 283.3 Th is also
FIG. 1. Comparative LC/MS and LC-MS/MS analysis of PEA standard, pipette extract, and foam extract by
triple quadrupole mass spectrometer. (A) Positive EIC chromatogram for the m/z 300.3 Th generated from a
5 lL injection of a 1 lM solution of PEA, 5 pmoles on column (trace a), of the pipette extract (trace b) and of the
foam extract (trace c); (B) MS/MS analysis in the positive ion mode of the peaks in panel A at RT = 5.7min
having m/z 300.3 Th. Panel A shows coeluting peaks at RT = 5.7. In panel B the MS/MS spectra show peaks
of the protonated PEA molecular ion [M+H]+ at m/z = 300.3 Th and of its two fragment: the molecular ion
arising from the water loss [M+H-H2O]+ at 282.3 Th and the ethanolamine-positive pseudomolecular ion
[Ethanolamine+H]+ at 62.1 Th. EIC, extracted ion chromatograms; LC/MS, liquid chromatography–mass
spectrometry; MS/MS, tandem mass spectrometry; PEA, palmitoylethanolamide; RT, retention time.
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visible except in trace a and b, but not c. Collectively,
results in Figure 1 demonstrate that one of the contam-
inants, present in the pipette and in the foam extracts,
gives rise to a signal detected by LC/MS analyses that is
attributable to PEA, having the same RT and MS/MS
fragmentation pattern of authentic standard.
To conﬁrm the presence of PEA as contaminant in
the pipettes and foam extracts, we also analyzed the
pure standard of PEA and the pipette extract on a dif-
ferent instrument capable of providing accurate mass
measurement up to the fourth decimal and with a
ppm deviation lower than 5 (Shimadzu IT-TOF). The
EIC for the high accurate exact mass of the positive
pseudomolecular ion of PEA [M+H]+ at 300.2897 Th
is shown in Figure 2. The spectra show coeluting
peaks at RT 6.3min for them/z 300.2897 with ppm de-
viation <5. The brute formula of this compound
was predicted by the Formula Predictor software as
C18H37NO2, both for the PEA standard and the con-
taminant in the pipette with a ppm deviation of 2.7
and 3.7, respectively (Supplementary Figs. S1 and S2).
This experiment unambiguously demonstrates the
presence of PEA as a contaminant in the glass Pasteur
pipette extract.
Other possible contaminants
To determine whether PEA was the only contaminant
present in glass pipettes, we analyzed the TIC of an
MS1 scan of the pipette washout. We performed this
analysis in the positive ion mode on the QQQ and in
both positive and negative ion mode on the IT-TOF
machine (Supplementary Figs. S3 and S4, respectively).
The analysis in the negative ion mode (Supplementary
Fig. S4, blue trace) clearly identiﬁed two peaks attribut-
able to palmitic acid and stearic acid by RT and accu-
rate exact mass (data not shown). Analysis in the
positive ion mode showed a number of peaks on both
instruments among which PEA is a contaminant. It
is outside the scope of this article to provide a com-
prehensive identiﬁcation of all contaminants, which
would require extensive structure elucidation work by
MS analysis. Importantly, however, analysis of other
FAEs and monoacylglycerols commonly studied in
the ECB ﬁeld resulted in no evidence of their presence
in foam (5mg). These analytes included: PEA for refer-
ence (Supplementary Fig. S5A, 100 pmol; Supplemen-
tary Fig. S5B, foam), OEA (Supplementary Fig. S5C,
100 pmol; Supplementary Fig. S5D, foam), AEA (Sup-
plementary Fig. S5E, 100pmol; Supplementary Fig. S5F,
foam), DHEA (Supplementary Fig. S5G, 100 pmol;
Supplementary Fig. S5H, foam), 2AG (Supplementary
Fig. S5I, 100 pmol; Supplementary Fig. S5J, foam),
and DHG (Supplementary Fig. S5K, 100 pmol; Supple-
mentary Fig. S5L, foam).
Quantitation of PEA in glass Pasteur pipettes
and in plastic foam
We quantiﬁed the amount of PEA that can be extracted
from a single glass pipette when washed with 8mL of
chloroform. Figure 3A shows proportional increase in
concentrated extracts of 1, 2, and 3 pipettes. We also
tested 9'' pipettes, where PEA was present in negligible
trace amount or absent. To quantify the PEA content
in each pipette we used an isotope dilution LC/MS
FIG. 2. Comparative LC/MS analysis by high-resolution accurate mass spectrometer. Positive EIC
chromatogram for the m/z 300.2897 Th (ppm dev <5) generated from a 2 lL injection of a 1 lM solution
of PEA, 2 pmoles on column (trace a) and of the pipette extract (trace b). The two chromatograms show
coeluting peaks for the interrogated m/z.
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method with acquisition in MRMmode as described in
the experimental procedures. PEA was quantiﬁed in
100 lL of concentrated washout of each pipette and re-
sults are expressed as pmol of PEA in the reconstituted
extract (Fig. 3A). We also quantiﬁed PEA content in pi-
pettes from different vendors (Supplementary Fig. S5).
Although the concentration of PEA increases with the
number of pipettes used in the extraction procedure,
the multiple experiments show a range of standard
deviations (SDs) in triplicate experiments. This is ob-
served also in pipettes produced by the same manufac-
turer and having the same lot number, but taken from
different boxes (Fig. 1 as compared with groups 1–2 in
Supplementary Fig. S6, showing independent experi-
ments in triplicate). The average amount of PEA pres-
ent in one pipette, calculated considering all nine
experiments shown in Figure 3 and Supplementary
Figure S6, is 33.4 – 4.02 pmol (mean – standard error
of mean, n = 9). Altogether, these results show that
one wash with 8mL of chloroform can extract an aver-
age amount of PEA of 33.4 pmol per pipette. Notably,
the SD within all pipette extraction experiments ranges
from 10 to 75% (average SD is around 30% in triplicate
experiments). This considerable data scattering indi-
cates that an extraction from a single pipette produced
by the samemanufacturer can give rise to PEA contam-
inations of very different extent. Finally, we employed
our LC/MS method to quantify the amount of contam-
inant PEA present in the polyurethane foam used to
wrap the glass pipettes. Figure 3B shows a strong linear
relationship between mass of foam insert and calcu-
lated PEA values.
Transfer of PEA from the foam to the glass
A washed clean glass Pasteur pipette was incubated in
contact with the foam as described in experimental
procedures. Pipette extractions with subsequent LC/
MS analysis were carried out before and after the wash-
ing step as well as after exposure to the foam. For
reference, the intensity (ion counts) of 100 pmol PEA
standard was 1.45e8 (Supplementary Fig. S7A). The
PEA signal was present in the unwashed pipette at
2.19e7 (Supplementary Fig. S7B), absent in the washed
pipette extract (Supplementary Fig. S7C) and present
again in the pipette exposed to 5mg foam at 1.56e6
(Supplementary Fig. S7D).
Discussion
A contaminant that is undistinguishable from PEA is
present in glass Pasteur pipettes in amounts that are
sufﬁcient to interfere with analysis of biological sam-
ples. The contaminant was identiﬁed based on its LC
retention time, accurate mass, and MS/MS fragmenta-
tion pattern, which were identical to those of authentic
PEA. By contrast, only a negligible PEA contamination
was found in 9'' Pasteur pipettes. Furthermore, we iso-
lated the PEA contamination to the polyurethane foam
used to package the pipettes, which is transferred to
glass pipettes by contact. In line with this ﬁnding,
Oddi et al.22 recently reported that FAEs can be
absorbed by plastic materials during laboratory assays.
It is therefore conceivable that FAEs incidentally
FIG. 3. Quantitation of PEA in extracts of
pipettes. (A) Each pipette was washed once
with 8mL of CHCl3. Number of pipettes washed
in each experiment is indicated in brackets.
Error bars represent SD, n = 3. The Fisher Pasteur
pipettes, 5†3 =4, were from lot n. 16168998
(Box 1). (B) Linear regression between mass of
foam insert and quantiﬁed PEA values. SD,
standard deviation.
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absorbed by plastics during industrial processes can
be released later in organic solvents. Lastly, no other
commonly analyzed FAEs or monoacylglycerols were
found to be present in the pipettes.
We published GC/MS23 and LC/MS5 analytical
methods for the quantitation of ECBs and other related
FAEs and monoacylglycerols in biological samples, in-
cluding human serum.6 Prompted by the need for a
novel quantitative LC/MS method to analyze ECBs in
blood, we reviewed the literature and noticed discrep-
ancies in the reported concentrations of FAEs and
ECBs in human blood serum and plasma (Table 1).
The EC50 for anandamide and 2AG vary depending
upon assay and tissue; however, it is important to
note that levels reported in Table 1 for both com-
pounds in plasma/serum are below the apparent bio-
logically active concentrations required to activate CB
receptors (see for comprehensive review of speciﬁc as-
says used by a variety of research groups24).
Regarding relative levels of PEA and OEA, a num-
ber of studies reported very similar concentrations
for both compounds,8–11,15 whereas others reported
PEA approximately twice higher than OEA.6,7,12,13,16,17
Regarding absolute values, two separate laboratories
reported levels of PEA and OEA in plasma that were
excessively high,18,19 which reached or exceeded the
concentrations needed by these ligands to engage
PPAR-a as agonists. PEA and OEA are, in fact, consid-
ered high-potency ligands of PPAR-a; in heterologous
expression systems, these FAEs engage the receptor
with median effective concentration (EC50) values of
0.12 lM for OEA and 3lM for PEA.25,26 In the above-
mentioned reports,18,19 although PEA levels did not ex-
ceed the EC50, levels of PEA were high relative to other
reports.6–17 The steady-state concentrations of FAEs
(and ECBs) in plasma/serum of healthy individuals pos-
sibly reﬂect an equilibrium of ECBs released by periph-
eral tissues and their enzymatic degradation in the blood
stream. In animal tissues (e.g., brain and upper small in-
testine), levels of PEA and OEA are present in the same
order of magnitude27,28; therefore, it was predictable to
ﬁnd a similar pattern in human serum or plasma, as
also shown by the literature reports in Table 1. Surpris-
ingly, in our preliminary experiments, the measured
level of OEA was in agreement with most literature re-
ports, whereas PEA was one order of magnitude higher
than expected (Table 1). This ﬁnding prompted us to
carefully screen all possible sources of contamina-
tion, including solvents, reagents, and glassware used
for lipid extraction and quantitative analysis.
In this study, we identify glass Pasteur pipettes (5''3 =4)
used to transfer solvents and lipid extracts as the source
of PEA contamination. The contaminant was identiﬁed
as PEA by its exact mass and RT in three similar but
different chromatographic systems, as well as by its
MS2 fragmentation pattern, which were identical to
those of standard PEA. Furthermore, we show that
PEA is present in the polyurethane foam that manufac-
turers use to wrap the pipettes before packing, from
which it leaks onto the glass pipettes. Moreover, accu-
rate exact mass measurements with ppm deviation
lower than ﬁve unambiguously conﬁrmed the identity
of the contaminant as PEA. Quantitative assessment
showed that the content of PEA is 33.4 – 4.02 pmol
per pipette. Unfortunately, none of the various manu-
facturers, whose pipettes were tested, provides 5''3 =4
glass Pasteur pipette that are contaminant free (Supple-
mentary Fig. S6). Only 9'' pipettes from one vendor
were free of PEA traces (Fig. 3A), allowing the use of
these consumables in the overall procedure.
The ﬁeld of lipidomics is rapidly developing;
however, reproducible standard procedures across lab-
oratories are not established. Therefore, it is not un-
common for lipidomics data to differ among from
independent laboratories.29 It is generally thought
that these discrepancies are a result of the use of differ-
ent instruments for lipid analysis, as well as differing
extraction and separation protocols. In this study, how-
ever, all results were conﬁrmed by two independent
laboratories using different LC systems and QQQ
mass spectrometers (Agilent 1200 LC system coupled
to an Agilent G6410A QQQ Mass Spectrometer in
the Piomelli laboratory, and the Waters ACQUITY
UPLC I-Class system coupled to a Xevo TQ-S QQQ
Mass Spectrometer in the DiPatrizio laboratory). Fur-
thermore, accurate mass data were acquired on a
third Shimadzu IT-TOF High-Resolution Mass Spec-
trometer for deﬁnitive conﬁrmation that the contami-
nant was indeed PEA. Another well-known issue in
lipidomics is that various sources of contamination can
originate artifacts. Lipids, especially fatty acids, are com-
mon contaminants in detergents, mineral oils, greases,
and plasticizers; hence, they are often present in labo-
ratory equipment, including glassware and solvents.
As shown in this study, assessment of FAEs, a group
of lipids with diverse signaling properties, is not
sheltered from this pitfall. We have shown that glass
Pasteur pipettes, commonly used in lipidomic labora-
tories to transfer lipid extracts and organic solvents,
can contain PEA as contaminant. This contamination
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gives rise to artifacts in the measurement of PEA in bi-
ological samples, especially when the procedure for
sample preparation includes fractionation of the lipid
extract, which concentrates the contaminant. The
scope of this study is an alert to the ECB and FAE sci-
entiﬁc community about possible PEA analytical arti-
facts and thus, great care is needed to exclude the
possibility of contaminants when analyzing endoge-
nous PEA levels in biological tissues.
Conclusion
In this study, we identiﬁed PEA as a quantitatively rel-
evant contaminant present in glass pipettes as well as in
the polyurethane foam used to wrap pipettes in the
packaging. We strongly recommend examining glass-
ware used to carry out the procedure by including in
analysis a ‘‘blank’’ extraction, whereby one additional
extract is subjected to the exact protocol of lipid extrac-
tion and processing, but with no biological sample
present. In particular, we warn readers to be cautious
with all plastic (foam) and glass materials that can re-
lease FAE-like compounds leading to an overestima-
tion of concentrations in biological samples. To avoid
these pitfalls it would be convenient to indicate vendors
in the material section for all consumables, including
glassware. High-quality certiﬁed disposable glassware
for LC/MS analysis is already on the market, but lim-
ited to vials and inserts. The present article shows
that there is an urgent need to expand the variety of
high-quality disposable glassware, including glass pi-
pettes, optimized for lipid extraction. In the meantime,
we additionally recommend including a washing step
of the glassware, with either chromosulfuric acid mix-
ture or chloroform, in the laboratory workﬂow.
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Abbreviations Used
2AG¼ 2-arachidonoyl-sn-glycerol
AEA¼ arachidonoylethanolamide, anandamide
CB¼ cannabinoid receptor
DHEA¼ docosahexaenoyl ethanolamide
DHG¼ docosahexaenoyl glycerol
ECBs¼ endocannabinoids
EIC¼ extracted ion chromatograms
ESI¼ electrospray ionization
FAEs¼ fatty acid ethanolamides
GC/MS¼ gas chromatography–mass spectrometry
ISTDs¼ deuterium-containing internal standards
IT-TOF¼ ion trap–time-of-ﬂight
LC/MS¼ liquid chromatography–mass spectrometry
MRM¼multiple reaction-monitoring
MS/MS¼ tandem mass spectrometry
OEA¼ oleoylethanolamide
PEA¼ palmitoylethanolamide
PPAR-a¼ peroxisome proliferator-activated receptor-a
QQQ¼ triple quadrupole
SD¼ standard deviation
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